Flow cytometry results: navigating pediatric immune profiles

Its value is narrower and more practical: rapid measurement of immune-cell populations, protein expression, and selected functional activity before molecular confirmation.

Flow cytometry interpretation for pediatric primary immunodeficiency depends on three variables: the child’s age, the measured immune compartment, and the analytical performance of the assay. A result that appears abnormal against an adult interval may be physiologic in an infant. Conversely, a mild numerical abnormality can become diagnostically significant when it aligns with an abnormal protein phenotype or a compatible clinical pattern.

Age-matched reference ranges are the first analytical requirement

Pediatric immune profiles are dynamic. The absolute and relative distribution of T cells, B cells, and natural killer cells changes across infancy, childhood, and adolescence. Naive and memory T-cell compartments also undergo substantial developmental shifts.

This makes reference selection part of the assay interpretation, not a secondary reporting detail.

The principal lymphocyte subsets usually evaluated in a pediatric immunophenotyping panel include:

• CD3+ T cells, representing the total T-cell compartment.
• CD4+ helper T cells, which support cellular and humoral immune responses.
• CD8+ cytotoxic T cells, involved in antiviral and cytotoxic immune activity.
• CD19+ or CD20+ B cells, representing the conventional B-cell compartment.
• CD56+ and/or CD16+ NK cells, representing natural killer cell populations.
• CD45RA+ naive and CD45RO+ memory T-cell subsets, used to characterize T-cell maturation and antigen-experienced populations.

The same absolute count can have different significance at different ages. The same is true for the ratio between subsets. Interpretation should therefore use reference intervals matched as closely as possible to age, specimen type, laboratory method, instrument configuration, and local validation data.

A pediatric laboratory may report either absolute counts, percentages, or both. Percentages describe the composition of the lymphocyte gate. Absolute counts are usually more useful for assessing clinically relevant lymphopenia, but they are dependent on the total lymphocyte count and the quality of the complete blood count used in the calculation.

Adult lymphocyte intervals are not a substitute for pediatric reference data. In infants, that substitution can convert normal developmental biology into a false abnormality.

Naive and memory T-cell phenotypes

CD45RA and CD45RO provide a simplified view of T-cell differentiation. In early life, naive T cells normally represent a larger proportion of the T-cell pool than they do later in childhood. Memory compartments expand with antigen exposure and immune maturation.

For this reason, an isolated reduction in CD45RO+ memory cells should not be interpreted without age context. The same result can indicate a different biological process in an infant than in an older child. A low proportion of naive cells may also be concerning in a setting where the expected pediatric profile contains a substantial naive compartment.

Reference intervals from historical pediatric studies, including work from the Pediatric AIDS Clinical Trials Group, remain useful as evidence of developmental variation. They do not create a universal cutoff applicable to every laboratory. Panel design, fluorochrome combinations, gating strategy, instrument calibration, and population characteristics affect the reported distribution.

From subset abnormalities to diagnostic clues

Flow cytometry is most informative when the laboratory translates an abnormal population into a testable immunological hypothesis. A low CD3+ count, for example, establishes T-cell lymphopenia. It does not independently establish the genetic cause.

The interpretation becomes more discriminating when several dimensions are considered together:

1. Absolute cell number

The laboratory determines whether the T-cell, B-cell, or NK-cell compartment is reduced in absolute terms.

2. Relative distribution

Percentages show whether one compartment is disproportionately represented or depleted.

3. T-cell maturation phenotype

Naive and memory markers provide information about developmental composition.

4. Surface protein expression

Absent, reduced, or abnormal expression can point toward defects in leukocyte development, signaling, adhesion, or cytotoxic function.

5. Intracellular protein expression

Intracellular staining can identify deficiencies that are not visible from basic cell counts.

6. Functional activity

Selected flow cytometry assays evaluate whether cells perform a defined function, rather than merely whether they are present.

7. Clinical and laboratory concordance

Immunoglobulin measurements, complete blood counts, infection history, vaccine responses, and genetic findings determine whether the flow result has diagnostic coherence.

A low cell count and a normal protein phenotype suggest a different pathway from a normal cell count with absent protein expression. Neither pattern should be interpreted in isolation.

Common patterns and their analytical meaning

This framework prevents a common reporting error: treating a descriptive immunophenotype as a final diagnosis. Flow cytometry provides a biological profile. Genetic sequencing may be required to determine the pathogenic variant, especially where several genes produce overlapping cellular phenotypes.

Flow cytometry after abnormal newborn screening

Newborn screening for severe combined immunodeficiency uses T-cell receptor excision circles, or TRECs. TRECs are episomal DNA products generated during T-cell receptor rearrangement. A low TREC result indicates reduced production or output of new T cells. It is a screening signal, not a complete immune diagnosis.

Follow-up flow cytometry is used to determine whether the infant has clinically significant T-cell lymphopenia and to characterize the remaining lymphocyte compartments. The follow-up assessment generally includes CD3+, CD4+, and CD8+ T cells, alongside B-cell and NK-cell populations. Naive and memory markers may add further information about T-cell maturation.

The transition from TREC screening to flow cytometry has several analytical stages:

• Screening threshold evaluation. The reported TREC value is interpreted against the program’s validated cutoff. Universal single cutoff values cannot be assumed across all screening systems.
• Specimen and clinical review. Prematurity, transfusion history, critical illness, and other clinical variables may affect the interpretation of an abnormal screen.
• Lymphocyte enumeration. Flow cytometry determines whether T-cell lymphopenia is present and quantifies the broader lymphocyte profile.
• Phenotypic clarification. Naive and memory markers, together with B-cell and NK-cell measurements, define the cellular pattern.
• Targeted functional or molecular testing. Additional assays and genetic sequencing are selected according to the observed phenotype.

The diagnostic purpose of this workflow is triage and clarification. TREC screening detects a risk pattern. Flow cytometry identifies the cellular abnormality. Functional assays and sequencing investigate mechanism.

A low TREC result does not always correspond to a single form of SCID. It can reflect other causes of T-cell lymphopenia, including syndromic, secondary, or transient conditions. Flow cytometry narrows the differential diagnosis but does not remove the need for clinical assessment and confirmatory testing.

TREC screening detects an abnormal output signal. Flow cytometry defines the lymphocyte phenotype. Sequencing addresses the molecular mechanism.

Surface and intracellular protein expression

Cell counts answer a limited question: which populations are present, and in what quantity? Protein-expression assays address a different question: whether a required immune protein is present on or inside the cell.

This distinction is central in disorders where lymphocytes or myeloid cells may be numerically preserved but functionally defective.

Leukocyte adhesion deficiency type I

Leukocyte Adhesion Deficiency type I is associated with impaired leukocyte adhesion and migration. Flow cytometry can evaluate expression of the relevant adhesion protein on leukocytes. Markedly reduced or absent expression provides a direct diagnostic clue that cannot be obtained from a basic lymphocyte subset count.

The interpretation still requires technical controls and appropriate antibody selection. Reduced expression can result from a pathogenic variant affecting protein production, trafficking, or surface stability. The protein phenotype should be correlated with clinical findings and confirmed through molecular testing.

Perforin deficiency

Perforin is a cytotoxic effector protein used by cytotoxic T cells and NK cells. Intracellular flow cytometry can evaluate perforin expression. Perforin deficiency, including the phenotype associated with familial hemophagocytic lymphohistiocytosis type 2, may be suggested by absent or markedly reduced intracellular staining.

A normal NK-cell count does not exclude a perforin defect. Numerical enumeration and intracellular protein expression measure different biological properties. Cytotoxicity testing may provide additional functional information, while sequencing can identify the relevant pathogenic variant.

Chronic granulomatous disease

Chronic granulomatous disease involves defective oxidative burst activity in phagocytes. Flow cytometry can evaluate this functional pathway using a stimulation-dependent oxidative burst assay. The result measures activity rather than simply cell number or protein presence.

An oxidative burst assay therefore belongs to the functional arm of flow cytometry. It requires appropriate stimulated and unstimulated controls, valid sample handling, and a laboratory capable of distinguishing absent, reduced, and heterogeneous activity patterns. The assay can provide a strong diagnostic clue, but the molecular subtype requires genetic analysis.

These examples illustrate why a single generic term, such as “normal flow cytometry,” is inadequate. A report should specify which populations, proteins, and functions were assessed. A normal basic lymphocyte panel does not imply normal cytotoxicity, oxidative burst, or intracellular protein expression.

WES, targeted panels, and the role of immunophenotyping

Flow cytometry and genetic sequencing are complementary methodologies. Their diagnostic utility differs by question.

A targeted gene panel has higher analytical focus. It is useful when the immunophenotype and clinical pattern point toward a defined group of genes. Whole-exome sequencing, or WES, evaluates a broader coding region and may be useful when the phenotype is nonspecific, atypical, or consistent with several possible disorders.

Neither approach eliminates the other.

Flow cytometry can improve the pretest logic for sequencing. A specific protein-expression defect may prioritize a narrower set of genes. Conversely, a pathogenic variant identified by sequencing may require flow cytometry to determine whether protein expression or cellular function is affected.

The sequence of testing is not universal. In an infant with abnormal TREC screening, flow cytometry is an immediate phenotyping tool. In a child with recurrent infections and a strong family history, sequencing may be initiated alongside immunophenotyping. In a patient with a known familial pathogenic variant, a targeted molecular assay may be more direct than broad sequencing.

Interpreting lymphocyte subset abnormalities in children

The clinical meaning of a flow cytometry result depends on magnitude, persistence, and pattern. A single abnormal specimen may be insufficient when the abnormality is mild or when pre-analytical conditions are uncertain.

Several sources of variability affect pediatric immune profiling:

• Age and developmental stage. Naive and memory T-cell distributions change throughout childhood.
• Absolute versus relative reporting. A percentage may appear preserved while the absolute count is low.
• Specimen quality. Delayed processing, inadequate cell viability, and poor sample handling can distort results.
• Instrument configuration. Laser settings, detector performance, compensation, and calibration influence signal separation.
• Antibody clone and panel design. Different reagents may produce different staining characteristics.
• Gating strategy. Debris, doublets, dead cells, and atypical populations can affect the final count.
• Reference population. Local demographic and laboratory-specific factors can shift reference intervals.
• Recent clinical events. Acute infection, immunosuppressive treatment, transfusion, and severe illness may alter cell distributions.

A technically strong report should make the analytical context visible. It should identify the measured populations, provide age-appropriate interpretation, distinguish absolute counts from percentages, and state whether the result is suggestive rather than definitive.

When a repeat specimen adds value

Repeat testing is useful when the result is inconsistent with the clinical context, when the abnormality is borderline, or when pre-analytical quality is uncertain. It is also useful when the first panel demonstrates an abnormal population but does not establish whether the finding is persistent.

Repeat testing should not function as a delay mechanism in a neonate with a strongly abnormal screening result or a clinically unstable child. The urgency of follow-up depends on the degree of lymphopenia, the clinical condition, and the suspected immune compartment.

The laboratory should avoid converting uncertainty into false precision. A result can be analytically valid while still being clinically indeterminate. This distinction is particularly important when the assay identifies a mild reduction without a coherent phenotype.

Diagnostic variability between laboratories

Flow cytometry is often described as a standardized technology. In practice, comparability depends on the complete analytical system. The instrument is only one component. Reagents, sample preparation, acquisition settings, gating templates, quality controls, and reference intervals all contribute to the final result.

Two laboratories may report different percentages for the same specimen if their panels or gating strategies differ. This does not automatically indicate that one result is incorrect. It does mean that serial monitoring is best performed with consistent methodology whenever possible.

For pediatric immunophenotyping, the following elements have direct practical value:

1. Panel definition

The report should specify whether the analysis covers basic lymphocyte enumeration, maturation markers, protein expression, or functional activity.

2. Age-specific reference framework

The laboratory should identify the pediatric interval used for interpretation rather than applying an adult range by default.

3. Absolute cell counts

Absolute values should be considered alongside percentages, especially when the question concerns lymphopenia.

4. Quality control documentation

Internal controls and assay validation support confidence in signal separation and population assignment.

5. Appropriate controls for functional assays

Functional tests require valid positive and negative controls. A failed control weakens interpretation even if the patient histogram appears clear.

6. Correlation with molecular testing

Flow findings should guide sequencing and help assess the biological relevance of identified variants.

7. Clear distinction between suggestive and confirmatory findings

A phenotypic pattern can support a diagnosis without proving it.

The clinical utility of flow cytometry is highest when the test is selected to answer a defined question. Ordering a broad panel without a diagnostic hypothesis can produce large amounts of descriptive data with limited specificity. Conversely, restricting testing to total lymphocyte counts can miss protein or functional defects in numerically preserved cells.

Clinical utility and limits of pediatric flow cytometry

Flow cytometry has four principal functions in the evaluation of childhood immune disorders:

• It provides rapid enumeration of T, B, and NK cells.
• It characterizes developmental T-cell phenotypes using naive and memory markers.
• It detects selected surface and intracellular protein abnormalities.
• It measures defined cellular functions, including oxidative burst activity.

Its limitations are equally clear. It does not replace genetic sequencing for final molecular diagnosis in all cases. It does not create a universal pediatric reference interval. It does not establish immune competence solely from the presence of a cell population. It does not convert an abnormal screening marker into a definitive disease label.

A clinically useful interpretation therefore follows a layered model:

• Screening identifies risk.
• Flow cytometry defines cellular phenotype.
• Functional assays test selected biological pathways.
• Genetic sequencing identifies or evaluates the molecular cause.
• Clinical correlation determines diagnostic relevance.

The most reliable reports maintain these boundaries. They describe what the assay measured, compare the result with an appropriate pediatric reference framework, identify the abnormalities that are genuinely discriminating, and specify which confirmatory tests remain necessary.

For pediatric primary immunodeficiency, flow cytometry is neither a generic count nor a standalone diagnosis. It is a structured immunophenotyping platform. Its performance depends on age-matched interpretation, validated assay design, and disciplined separation of numerical, phenotypic, and functional evidence. That is the basis of its clinical utility in newborn screening follow-up, pediatric laboratory medicine, and the evaluation of suspected inborn errors of immunity.